Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants
Sponsor: OPKO Health, Inc.
Summary
Two-part Phase 1/2 study of OPK-88006, including an open-label SAD phase in healthy participants and a double-blind, randomized, placebo-controlled MAD phase in participants with presumed MASH, to evaluate safety, PK, and MASH related pharmacodynamic changes compared to placebo.
Official title: Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of OPK-88006 in Healthy and Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) Participants
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-12
Completion Date
2027-12
Last Updated
2026-04-06
Healthy Volunteers
Yes
Conditions
Interventions
OPK-88006
Administered by subcutaneous injection
Placebo
Administered by subcutaneous injection